What this trial means for you
This study is opening soon at 11 US sites. It's studying Cagrilintide, Placebo cagrilintide, Placebo semaglutide for overweight, obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion criteria: * History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). * Previous dosing of marketed or non-marketed amylin-based compounds. * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.
Study sites by state
Georgia
- Hope Clin Res & Wellness, Conyers
Hawaii
- East West Med Res Inst, Honolulu
Illinois
- Walgreens - Store 11760, Oak Park
Indiana
- Midwest Inst For Clin Res, Indianapolis
Kentucky
- The Alliance for Multispecialty Research LLC AMR, Lexington
North Carolina
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
South Carolina
- Coastal Carolina Res Ctr, North Charleston
Virginia
- Health Res of Hampton Roads, Newport News
- National Clin Res Inc., Richmond
- Selma Medical Associates, Winchester
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.